Drug intelligence / Profile preview

WT-3

Development stage: Preclinical
Lead developer: Hangzhou Westan Pharmaceutical Technology
Modality: Small Molecules

Overview

WT-3 is a small molecule drug candidate being developed by Hangzhou Westan Pharmaceutical Technology for the treatment of pulmonary fibrosis. It is currently in the preclinical stage of development, specifically undergoing druggability optimization. The drug is part of Westan's pipeline focused on innovative therapies for fibrotic diseases, which includes other candidates such as WT-1 and WT-2. While the company targets key pathways involved in the progression of fibrosis, the specific molecular target and mechanism of action for WT-3 have not been publicly disclosed.

Targets

P2X3 (P2X purinoceptor 3)

Beyond the preview

Go deeper on WT-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT-3.

Explore the full profile